Modeling the interactions between α;1-adrenergic receptors and their antagonists

Current Computer-Aided Drug Design

Volumn 6, Issue 3, 2010, Pages 165-178

  Du, Lupei ^a   Li, Minyong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Homology modeling; Molecular docking; Molecular modeling; Pharmacophore

Indexed keywords

COMPUTATIONAL CHEMISTRY; LIGANDS; MOLECULAR BIOLOGY; PHARMACODYNAMICS;

ADRENERGIC RECEPTORS; BENIGN PROSTATIC HYPERPLASIA; G PROTEIN COUPLED RECEPTORS; GLUCOSE METABOLISM; HOMOLOGY MODELING; LIGAND BINDING; MOLECULAR DOCKING; PHARMACOPHORES; PHYSIOLOGICAL PROCESS; SMOOTH MUSCLE CONTRACTIONS;

MOLECULAR MODELING;

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 3 [3 [4 [4 FLUORO 2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 5 METHYL 1H PYRIMIDINE 2,4 DIONE; 4 AMINO 2 [4 BENZYLOXYCARBONYL 3 [(TERT BUTYLAMINO)CARBONYL] 1 PIPERAZINYL] 6,7 DIMETHOXYQUINAZOLINE; 5 METHYLUROPIDIL; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; AH 1100OA; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARPIPRAMINE; CYCLAZOSIN; DOXAZOSIN; ERGOTAMINE; ETOPERIDONE; GG 818; INDORAMIN; N [5 (4,5 DIHYDRO 1H IMIDAZOL 2 YL) 5,6,7,8 TETRAHYDRO 2 HYDROXY 1 NAPHTHYL]METHANESULFONAMIDE; NIGULDIPINE; PRAZOSIN; RWJ 69736; SILODOSIN; SNAP 7915; TAMSULOSIN; TERAZOSIN; TRAZODONE; UNCLASSIFIED DRUG; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; LIGAND;

ARTICLE; COMPARATIVE STUDY; DRUG ACTIVATION; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; EXPERIMENTAL STUDY; HUMAN; HYDROGEN BOND; MOLECULAR DOCKING; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER AIDED DESIGN; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG DESIGN; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN CONFORMATION; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; AMINO ACID SEQUENCE; ANIMALS; COMPUTER SIMULATION; COMPUTER-AIDED DESIGN; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 78049526134     PISSN: 15734099     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340910791760082     Document Type: Article

References (100)

1. Bylund, D.B.; Eikenberg, D.C.; Hieble, J.P.; Langer, S.Z.;Lefkowitz, R.J.; Minneman, K.P.; Molinoff, P.B.; Ruffolo Jr., R.R.; Trendelenburg, U. International Union of Pharmacologynomenclature of adrenoceptors. Pharmacol. Rev., 1994, 46, 121-136.
2. Hieble, J.P.; Bylund, D.B.; Clarke, D.E.; Eikenburg, D.C.; Langer, S.Z.;Lefkowitz, R.J.; Minneman, K.P; Ruffolo Jr., R.R.International Union of Pharmacology. X. Recommendation fornomenclature of α 1-adrenoceptors: consensus update.Pharmacol. Rev., 1995, 47, 267-270.
3. Docherty, J.R. Subtypes of functional α1-adrenoceptor. Mol. Life Sci., 2010, 67, 405-417.
4. Zhong, H.; Minneman, K.P. α1-adrenoceptor subtypes. Eur. J.Pharmacol., 1999, 375, 261-276.
5. Koshimizu, T.A.; Tanoue, A.; Hirasawa, A.; Yamauchi, J.;Tsujimoto, G. Recent advances in α1-adrenoceptorpharmacology. Pharmacol. Ther., 2003, 98, 235-244.
6. Campagne, F.; Weinstein, H. Schematic representation of residue-based protein context-dependent data: an application totransmembrane proteins. J. Mol. Graph. Model., 1999, 17, 207-213.
7. Ruffolo Jr., R.R.; Hieble, J.P. Adrenoceptor pharmacology:urogenital applications. Eur. Urol., 1999, 36 Suppl 1, 17-22.
8. Jarajapu, Y.P.; Johnston, F.; Berry, C.; Renwick, A.; McGrath, J.C.; MacDonald, A.; Hillier, C. Functional characterization ofα1-adrenoceptor subtypes in human subcutaneous resistancearteries. J. Pharmacol. Exp. Ther., 2001, 299, 729-734.
9. Goepel, M.; Krege, S.; Price, D.T.; Michelotti, G.A.; Schwinn, D.A.; Michel, M.C. Characterization of α-adrenoceptorsubtypes in the corpus cavernosum of patients undergoing sexchange surgery. J. Urol., 1999, 162, 1793-1799.
10. Kyprianou, N.; Benning, C.M. Suppression of human prostatecancer cell growth by α1-adrenoceptor antagonists doxazosinand terazosin via induction of apoptosis. Cancer Res., 2000, 60,4550-4555.
11. Benning, C.M.; Kyprianou, N. Quinazoline-derived α1-adrenoceptor antagonists induce prostate cancer cell apoptosis viaan α1-adrenoceptor-independent action. Cancer Res., 2002, 62,597-602.
12. Rosini, M.; Bolognesi, M.L.; Giardina, D.; Minarini, A.; Tumiatti, V.; Melchiorre, C. Recent advances in α1-adrenoreceptorantagonists as pharmacological tools and therapeutic agents. Curr.Top. Med. Chem., 2007, 7, 147-162.
13. Jain, K.S.; Bariwal, J.B.; Kathiravan, M.K.; Phoujdar, M.S.; Sahne, R.S.; Chauhan, B.S.; Shah, A.K.; Yadav, M.R. Recent advances inselective α1-adrenoreceptor antagonists as antihypertensiveagents. Bioorg. Med. Chem., 2008, 16, 4759-4800.
14. Lachnit, W.G.; Tran, A.M.; Clarke, D.E.; Ford, A.P.Pharmacological characterization of an α 1A-adrenoceptormediating contractile responses to noradrenaline in isolated caudalartery of rat. Br. J. Pharmacol., 1997, 120, 819-826.
15. Shibata, K.; Foglar, R.; Horie, K.; Obika, K.; Sakamoto, A.; Ogawa, S.; Tsujimoto, G. KMD-3213, a novel, potent, α 1a-adrenoceptor-selective antagonist: characterization usingrecombinant human α 1-adrenoceptors and native tissues. Mol.Pharmacol., 1995, 48, 250-258.
16. Marucci, G.; Angeli, P.; Buccioni, M.; Gulini, U.; Melchiorre, C.; Sagratini, G.; Testa, R.; Giardina, D. (+)-Cyclazosin, a selectiveα(1B)-adrenoceptor antagonist: Functional evaluation in rat andrabbit tissues. Eur. J. Pharmacol., 2005, 522, 100-107.
17. Patane, E.; Pittala, V.; Guerrera, F.; Salerno, L.; Romeo, G.; Siracusa, M.A.; Russo, F.; Manetti, F.; Botta, M.; Mereghetti, I.; Cagnotto, A.; Mennini, T. Synthesis of 3-arylpiperazinylalkylpyrrolo [3,2-d]pyrimidine-2,4-dione derivativesas novel, potent, and selective a1-adrenoceptor ligands. J. Med.Chem., 2005, 48, 2420-2431.
18. Satoh, M.; Enomoto, K.; Takayanagi, I.; Koike, K. Differences ofantagonism for a selective α1D-adrenoceptor antagonist BMY7378 in the rabbit thoracic aorta and iliac artery. J. Smooth MuscleRes., 1998, 34, 151-158.
19. Leonardi, A.; Barlocco, D.; Montesano, F.; Cignarella, G.; Motta, G.; Testa, R.; Poggesi, E.; Seeber, M.; De Benedetti, P.G.; Fanelli, F. Synthesis, screening, and molecular modeling of new potent andselective antagonists at the α 1d adrenergic receptor. J. Med.Chem., 2004, 47, 1900-1918.
20. Shi, L.; Javitch, J.A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and secondextracellular loop. Annu. Rev. Pharmacol. Toxicol., 2002, 42, 437-467.
21. Ruffolo, R.R., Jr.; Rice, P.J.; Patil, P.N.; Hamada, A.; Miller, D.D.Differences in the applicability of the easson-stedman hypothesis tothe α 1- and α 2-adrenergic effects of phenethylamines andimidazolines. Eur. J. Pharmacol., 1983, 86, 471-475.
22. Ruffolo, R.R., Jr.; Banning, J.W.; Patil, P.N.; Hamada, A.; Miller, D.D. Evaluation of the adrenergic effects of a novel optically activecatecholamidine in vitro and in vivo: differential application of theEasson-Stedman hypothesis to α and beta adrenoceptors. J.Pharmacol. Exp. Ther., 1983, 226, 469-476.
23. Waugh, D.J.; Gaivin, R.J.; Zuscik, M.J.; Gonzalez-Cabrera, P.;Ross, S.A.; Yun, J.; Perez, D.M. Phe-308 and Phe-312 intransmembrane domain 7 are major sites of α 1-adrenergicreceptor antagonist binding. Imidazoline agonists bind likeantagonists. J. Biol. Chem., 2001, 276, 25366-25371.
24. Wetzel, J.M.; Salon, J.A.; Tamm, J.A.; Forray, C.; Craig, D.; Nakanishi, H.; Cui, W.; Vaysse, P.J.; Chiu, G.; Weinshank, R.L.; Hartig, P.R.; Branchek, T.A.; Gluchowski, C. Modeling andmutagenesis of the human α 1a-adrenoceptor: orientation andfunction of transmembrane helix V sidechains. Receptor Channel,1996, 4, 165-177.
25. McCune, D.; Gaivin, R.; Rorabaugh, B.; Perez, D. Bulk is adeterminant of oxymetazoline affinity for the α1A-adrenergicreceptor. Receptors Channels, 2004, 10, 109-116.
26. Hwa, J.; Perez, D.M. The unique nature of the serine interactionsfor α 1-adrenergic receptor agonist binding and activation. J.Biol. Chem., 1996, 271, 6322-6327.
27. Perez, D.M. Structure-function of α1-adrenergic receptors.Biochem. Pharmacol., 2007, 73, 1051-1062.
28. Ahmed, M.; Hossain, M.; Bhuiyan, M.A.; Ishiguro, M.; Tanaka, T.; Muramatsu, I.; Nagatomo, T. Mutational analysis of the α 1a-adrenergic receptor binding pocket of antagonists by radioligandbinding assay. Biol. Pharm. Bull., 2008, 31, 598-601.
29. Cavalli, A.; Fanelli, F.; Taddei, C.; De Benedetti, P.G.; Cotecchia, S. Amino acids of the α1B-adrenergic receptor involved inagonist binding: differences in docking catecholamines to receptorsubtypes. FEBS Lett., 1996, 399, 9-13.
30. Takahashi, K.; Hossain, M.; Ahmed, M.; Bhuiyan, M.A.; Ohnuki, T.; Nagatomo, T. Asp125 and Thr130 in transmembrane domain 3are major sites of α1b-adrenergic receptor antagonist binding.Biol. Pharm. Bull., 2007, 30, 1891-1894.
31. Chen, S.; Xu, M.; Lin, F.; Lee, D.; Riek, P.; Graham, R.M. Phe310in transmembrane VI of the α1B-adrenergic receptor is a keyswitch residue involved in activation and catecholamine ringaromatic bonding. J. Biol. Chem., 1999, 274, 16320-16330.
32. Nagaoka, Y.; Ahmed, M.; Hossain, M.; Bhuiyan, M.A.; Ishiguro, M.; Nakamura, T.; Watanabe, M.; Nagatomo, T. Amino acids ofthe human α1d-adrenergic receptor involved in antagonistbinding. J. Pharmacol. Sci., 2008, 106, 114-120.
33. Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochemistry, 2002, 3, 928-944.
34. Andricopulo, A.D.; Salum, L.B.; Abraham, D.J. Structure-baseddrug design strategies in medicinal chemistry. Curr. Top. Med.Chem., 2009, 9, 771-790.
35. Gregori-Puigjane, E.; Mestres, J. A ligand-based approach tomining the chemogenomic space of drugs. Comb. Chem. High.Throughput Screen., 2008, 11, 669-676.
36. Apostolakis, J.; Caflisch, A. Computational ligand design. Comb.Chem. High. Throughput Screen., 1999, 2, 91-104.
37. Leach, A.R.; Gillet, V.J.; Lewis, R.A.; Taylor, R. Three-dimensional pharmacophore methods in drug discovery. J. Med.Chem., 2010, 53, 539-558.
38. Dror, O.; Shulman-Peleg, A.; Nussinov, R.; Wolfson, H.J. Predicting molecular interactions in silico: I. A guide topharmacophore identification and its applications to drug design.Curr. Med. Chem., 2004, 11, 71-90.
39. Wolber, G.; Seidel, T.; Bendix, F.; Langer, T. Molecule-pharmacophore superpositioning and pattern matching incomputational drug design. Drug Discov. Today, 2008, 13, 23-29.
40. Li, H.; Sutter, J.; Hoffmann, R. HypoGen: an automated system forgenerating 3D predictive pharmacophore models. InPharmacophore Preception, Development and Use in DrugDesign, Guner, O.F.; Ed. International University Line: La Jolla,CA, 2000; pp. 171-189.
41. Clement, O.O.; Mehl, A.T. HipHop: pharmacophores based onmultiple common-feature alignments. In PharmacophorePerception, Development & Use In Drug Design, InternationalUniversity Line: 2000; Vol. 2, pp. 69-84.
42. Martin, Y.C.; Bures, M.G.; Danaher, E.A.; DeLazzer, J.; Lico, I.; Pavlik, P.A. A fast new approach to pharmacophore mapping andits application to dopaminergic and benzodiazepine agonists. J.Comput. Aided Mol. Des., 1993, 7, 83-102.
43. Jones, G.; Willett, P.; Glen, R.C. GASP: genetic algorithmsuperimposition program. In Pharmacophore Perception,Development & Use In Drug Design, Guner, O.F.; Ed. InternationalUniversity Line: La Jolla, CA, 2000, Vol. 2, pp. 85-106.
44. Richmond, N.J.; Abrams, C.A.; Wolohan, P.R.; Abrahamian, E.; Willett, P.; Clark, R.D. GALAHAD: 1. pharmacophoreidentification by hypermolecular alignment of ligands in 3D. J.Comput. Aided Mol. Des., 2006, 20, 567-87.
45. Dixon, S.L.; Smondyrev, A.M.; Rao, S.N. PHASE: a novelapproach to pharmacophore modeling and 3D database searching.Chem. Biol. Drug Des., 2006, 67, 370-372.
46. Dixon, S.L.; Smondyrev, A.M.; Knoll, E.H.; Rao, S.N.; Shaw, D.E.; Friesner, R.A. PHASE: a new engine for pharmacophoreperception, 3D QSAR model development, and 3D databasescreening: 1. Methodology and preliminary results. J. Comput.Aided Mol. Des., 2006, 20, 647-671.
47. Patel, Y.; Gillet, V.J.; Bravi, G.; Leach, A.R. A comparison of thepharmacophore identification programs: Catalyst, DISCO andGASP. J. Comput. Aided Mol. Des., 2002, 16, 653-681.
48. Poptodorov, K.; Luu, T.; Hoffmann, R.D. Pharmacophore ModelGeneration Software Tools. In Pharmacophores andPharmacophore Searches, Langer, T.; Hoffmann, R.D.; Eds.WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim, 2006; pp.15-47.
49. Fang, H.; Lu, J.F.; Xia, L. Constructing biophore of uroselectivea1-adrenoceptor antagonist. J. Chin. Pharm. Sci., 2003, 12, 188-191.
50. Wang, T.; Zhou, J. 3DFS: a new 3D flexible searching system foruse in drug design. J. Chem. Inf. Comput. Sci., 1998, 38, 71-77.
51. Li, M.Y.; Fang, H.; Xia, L. Pharmacophore-based design,synthesis, biological evaluation, and 3D-QSAR studies of aryl-piperazines as α(1)-adrenoceptor antagonists. Bioorg. Med.Chem. Lett., 2005, 15, 3216-32169.
52. Wu, B.; Li, M.Y.; Jiang, Z.Z.; Xia, L. Design, synthesis and 3D-QSAR study of 2-[N '-(2-aryloxyethyl)piperazinomethyl]-benzoxazole series as 1-adrenoceptor antagonists. Acta Chim.Sinica, 2004, 62, 1430-1436.
53. Wu, B.; Li, M.Y.; Jiang, Z.Z.; Xia, L. Design, synthesis and 3D-QSAR study of N-substituted-3-indolyl-acetamide series as 1-adrenoceptor antagonists. Chinese J. Org. Chem., 2004, 24, 1587-1594.
54. Fang, H.; Li, M.Y.; Xia, L. Pharmacophore-guided design,synthesis and evaluation of quinazoline-arylpiperazines as newα(1)-adrenoceptor antagonists. Chinese Chem. Lett., 2007, 18,41-44.
55. Li, M.Y.; Xia, L. Rational design, synthesis, biologic evaluation,and structure-activity relationship studies of novel 1-indanoneα(1)-adrenoceptor antagonists. Chem. Biol. Drug Des., 2007,70, 461-464.
56. Barbaro, R.; Betti, L.; Botta, M.; Corelli, F.; Giannaccini, G.; Maccari, L.; Manetti, F.; Strappaghetti, G.; Corsano, S. Synthesis,Biological Evaluation, and Pharmacophore Generation of NewPyridazinone Derivatives with Affinity toward a1- and a2-Adrenoceptors. J. Med. Chem., 2001, 44, 2118-2132.
57. Giannangeli, M.; Cazzolla, N.; Luparini, M.R.; Magnani, M.; Mabilia, M.; Picconi, G.; Tomaselli, M.; Baiocchi, L. Effect ofmodifications of the alkylpiperazine moiety of trazodone on5HT2A and α1 receptor binding affinity. J. Med. Chem., 1999,42, 336-345.
58. Costa, A.; Martignoni, E.; Blandini, F.; Petraglia, F.; Genazzani, A.R.; Nappi, G. Effects of etoperidone on sympathetic andpituitary-adrenal responses to diverse stressors in humans. Clin.Neuropharmacol., 1993, 16, 127-138.
59. Setoguchi, M.; Sakamori, M.; Takehara, S.; Fukuda, T. Effects ofiminodibenzyl antipsychotic drugs on cerebral dopamine andα-adrenergic receptors. Eur. J. Pharmacol., 1985, 112, 313-322.
60. Roquebert, J.; Grenie, B. α 2-adrenergic agonist and α 1-adrenergic antagonist activity of ergotamine anddihydroergotamine in rats. Arch. Int. Pharmacodyn. Ther., 1986,284, 30-37.
61. Bremner, J.B.; Coban, B.; Griffith, R. Pharmacophore developmentfor antagonists at 1 adrenergic receptor subtypes. J. Comput.Aided Mol. Des., 1996, 10, 545-557.
62. Bremner, J.B.; Coban, B.; Griffith, R.; Groenewoud, K.M.; Yates, B.F. Ligand design for 1-adrenoceptor subtype selectiveantagonists. Bioorg. Med. Chem., 2000, 8, 201-214.
63. MacDougall, I.J.; Griffith, R. Selective pharmacophore design forα1-adrenoceptor subtypes. J. Mol. Graph. Model., 2006, 25,146-157.
64. Li, M.Y.; Tsai, K.C.; Xia, L. Pharmacophore identification ofα(1A)-adrenoceptor antagonists. Bioorg. Med. Chem. Lett.,2005, 15, 657-664.
65. Tropsha, A.; Golbraikh, A. Predictive QSAR modeling workflow,model applicability domains, and virtual screening. Curr. Pharm.Des., 2007, 13, 3494-3504.
66. Selassie, C.D.; Mekapati, S.B.; Verma, R.P. QSAR: then and now.Curr. Top. Med. Chem., 2002, 2, 1357-13579.
67. Gedeck, P.; Lewis, R.A. Exploiting QSAR models in leadoptimization. Curr. Opin. Drug Discov. Devel., 2008, 11, 569-575.
68. Du, Q.S.; Huang, R.B.; Chou, K.C. Recent advances in QSAR andtheir applications in predicting the activities of chemical molecules,peptides and proteins for drug design. Curr. Protein Pept. Sci.,2008, 9, 248-260.
69. Eric, S.; Solmajer, T.; Zupan, J.; Novic, M.; Oblak, M.; Agbaba, D.Quantitative structure-activity relationships of a1-adrenergicantagonists. J. Mol. Model., 2004, 10, 139-150.
70. Menziani, M.C.; Montorsi, M.; De Benedetti, P.G.; Karelson, M.Relevance of theoretical molecular descriptors in quantitativestructure-activity relationship analysis of a1-adrenergic receptorantagonists. Bioorg. Med. Chem., 1999, 7, 2437-2451.
71. Cinone, N.; Carrieri, A.; Strappaghetti, G.; Corsano, S.; Barbaro, R.; Carotti, A. Comparative molecular field analysis of somepyridazinone-containing α1-antagonists. Bioorg. Med. Chem.,1999, 7, 2615-2620.
72. Li, M.Y.; Du, L.P.; Wu, B.; Xia, L. Self-organizing molecular fieldanalysis on a1a-adrenoceptor dihydropyridine antagonists. Bioorg.Med. Chem., 2003, 11, 3945-3951.
73. Ginalski, K. Comparative modeling for protein structure prediction.Curr. Opin. Struct. Biol., 2006, 16, 172-177.
74. Patny, A.; Desai, P.V.; Avery, M.A. Homology modeling of G-protein-coupled receptors and implications in drug design. Curr.Med. Chem., 2006, 13, 1667-1691.
75. Simms, J.; Hall, N.E.; Lam, P.H.; Miller, L.J.; Christopoulos, A.; Abagyan, R.; Sexton, P.M. Homology modeling of GPCRs.Methods Mol. Biol., 2009, 552, 97-113.
76. Hillisch, A.; Pineda, L.F.; Hilgenfeld, R. Utility of homologymodels in the drug discovery process. Drug Discov. Today, 2004,9, 659-669.
77. Cavasotto, C.N.; Phatak, S.S. Homology modeling in drugdiscovery: current trends and applications. Drug Discov. Today,2009, 14, 676-683.
78. Gouaux, E. It's not just a phase: crystallization and X-ray structuredetermination of bacteriorhodopsin in lipidic cubic phases.Structure, 1998, 6, 5-10.
79. Pebay-Peyroula, E.; Rummel, G.; Rosenbusch, J.P.; Landau, E. M. X-ray structure of bacteriorhodopsin at 2.5 angstroms frommicrocrystals grown in lipidic cubic phases. Science, 1997, 277,1676-1681.
80. Kamikubo, H.; Kataoka, M.; Varo, G.; Oka, T.; Tokunaga, F.; Needleman, R.; Lanyi, J.K. Structure of the N intermediate ofbacteriorhodopsin revealed by x-ray diffraction. Proc. Natl. Acad.Sci. USA, 1996, 93, 1386-1390.
81. Pardo, L.; Ballesteros, J.A.; Osman, R.; Weinstein, H. On the useof the transmembrane domain of bacteriorhodopsin as a templatefor modeling the three-dimensional structure of guanine nucleotide-binding regulatory protein-coupled receptors. Proc. Natl. Acad. Sci.USA, 1992, 89, 4009-4012.
82. Davies, A.; Schertler, G.F.; Gowen, B.E.; Saibil, H.R. Projectionstructure of an invertebrate rhodopsin. J. Struct. Biol., 1996, 117,36-44.
83. Bosch, L.; Iarriccio, L.; Garriga, P. New prospects for drugdiscovery from structural studies of rhodopsin. Curr. Pharm. Des.,2005, 11, 2243-2256.
84. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, H.; Fox, B.A.; Le Trong, I.; Teller, D.C.; Okada, T.; Stenkamp, R.E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: AG protein-coupled receptor. Science, 2000, 289, 739-745.
85. Li, M.Y.; Lu, J.F.; Xia, L. Receptor-based molecular modelingstudy on antagonist-bound human 1A, 1B and 1D-adrenoceptors.Acta Chim. Sinica, 2005, 63, 1875-1883.
86. Ishiguro, M.; Futabayashi, Y.; Ohnuki, T.; Ahmed, M.; Muramatsu, I.; Nagatomo, T. Identification of binding sites of prazosin,tamsulosin and KMD-3213 with α(1)-adrenergic receptorsubtypes by molecular modeling. Life Sci., 2002, 71, 2531-2541.
87. Kinsella, G.K.; Rozas, I.; Watson, G.W. Computationaldevelopment of an α1A-adrenoceptor model in a membranemimic. Biochem. Biophys. Res. Commun., 2004, 324, 916-921.
88. Pedretti, A.; Elena Silva, M.; Villa, L.; Vistoli, G. Binding siteanalysis of full-length α1a adrenergic receptor using homologymodeling and molecular docking. Biochem. Biophys. Res.Commun., 2004, 319, 493-500.
89. Notredame, C.; Higgins, D.G.; Heringa, J. T-Coffee: A novelmethod for fast and accurate multiple sequence alignment. J. Mol.Biol., 2000, 302, 205-217.
90. Gouet, P.; Robert, X.; Courcelle, E. ESPript/ENDscript: Extractingand rendering sequence and 3D information from atomic structuresof proteins. Nucleic Acids Res., 2003, 31, 3320-3323.
91. Cherezov, V.; Rosenbaum, D.M.; Hanson, M.A.; Rasmussen, S.G.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Kuhn, P.; Weis, W.I.; Kobilka, B.K.; Stevens, R.C. High-resolution crystal structure of anengineered human beta2-adrenergic G protein-coupled receptor.Science, 2007, 318, 1258-1265.
92. Rosenbaum, D.M.; Cherezov, V.; Hanson, M.A.; Rasmussen, S.G.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Yao, X.J.; Weis, W.I.; Stevens, R.C.; Kobilka, B.K. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptorfunction. Science, 2007, 318, 1266-1273.
93. Rasmussen, S.G.; Choi, H.J.; Rosenbaum, D.M.; Kobilka, T.S.; Thian, F.S.; Edwards, P.C.; Burghammer, M.; Ratnala, V.R.; Sanishvili, R.; Fischetti, R.F.; Schertler, G.F.; Weis, W.I.; Kobilka, B.K. Crystal structure of the human beta2 adrenergic G-proteincoupled receptor. Nature, 2007, 450, 383-387
94. Jaakola, V.P.; Griffith, M.T.; Hanson, M.A.; Cherezov, V.; Chien, E.Y.; Lane, J.R.; Ijzerman, A.P.; Stevens, R.C. The 2.6 angstromcrystal structure of a human A2A adenosine receptor bound to anantagonist. Science, 2008, 322, 1211-1217.
95. Warne, T.; Serrano-Vega, M.J.; Baker, J.G.; Moukhametzianov, R.; Edwards, P.C.; Henderson, R.; Leslie, A.G.; Tate, C.G.; Schertler, G.F. Structure of a beta1-adrenergic G-protein-coupled receptor.Nature, 2008, 454, 486-491.
96. Kobilka, B.; Schertler, G.F. New G-protein-coupled receptorcrystal structures: insights and limitations. Trends Pharmacol. Sci.,2008, 29, 79-83.
97. Rosenbaum, D.M.; Rasmussen, S.G.; Kobilka, B.K. The structureand function of G-protein-coupled receptors. Nature, 2009, 459,356-363.
98. Mobarec, J.C.; Sanchez, R.; Filizola, M. Modern homologymodeling of G-protein coupled receptors: which structural templateto use? J. Med. Chem., 2009, 52, 5207-5216.
99. Li, M.Y.; Fang, H.; Du, L.P.; Xia, L.; Wang, B.H. Computationalstudies of the binding site of 1A-adrenoceptor antagonists. J. Mol.Model., 2008, 14, 957-966.
100. Bremner, J.B.; Griffith, R.; Coban, B. Ligand design for α(1)adrenoceptors. Curr. Med. Chem., 2001, 8, 607-620.